JP2008536499A - ブタサーコウイルス産生アッセイ - Google Patents
ブタサーコウイルス産生アッセイ Download PDFInfo
- Publication number
- JP2008536499A JP2008536499A JP2008506739A JP2008506739A JP2008536499A JP 2008536499 A JP2008536499 A JP 2008536499A JP 2008506739 A JP2008506739 A JP 2008506739A JP 2008506739 A JP2008506739 A JP 2008506739A JP 2008536499 A JP2008536499 A JP 2008536499A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- circovirus
- orf2
- adherent
- orf1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 42
- 241000202347 Porcine circovirus Species 0.000 title description 25
- 238000003556 assay Methods 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 90
- 241001533384 Circovirus Species 0.000 claims abstract description 77
- 238000004113 cell culture Methods 0.000 claims abstract description 50
- 239000000427 antigen Substances 0.000 claims abstract description 35
- 102000036639 antigens Human genes 0.000 claims abstract description 35
- 108091007433 antigens Proteins 0.000 claims abstract description 35
- 239000006228 supernatant Substances 0.000 claims abstract description 19
- 238000010978 in-process monitoring Methods 0.000 claims abstract description 16
- 238000003306 harvesting Methods 0.000 claims abstract description 12
- 230000001464 adherent effect Effects 0.000 claims description 66
- 108700026244 Open Reading Frames Proteins 0.000 claims description 34
- 239000000758 substrate Substances 0.000 claims description 32
- 230000003833 cell viability Effects 0.000 claims description 25
- 238000011218 seed culture Methods 0.000 claims description 24
- 238000012544 monitoring process Methods 0.000 claims description 21
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 claims description 16
- 238000000684 flow cytometry Methods 0.000 claims description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 10
- 239000012894 fetal calf serum Substances 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 5
- 241001673669 Porcine circovirus 2 Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 50
- 230000003612 virological effect Effects 0.000 abstract description 16
- 238000011534 incubation Methods 0.000 abstract description 15
- 241001465754 Metazoa Species 0.000 abstract description 7
- 239000007787 solid Substances 0.000 abstract description 5
- 239000006143 cell culture medium Substances 0.000 abstract description 4
- 230000035899 viability Effects 0.000 abstract description 3
- 239000012679 serum free medium Substances 0.000 abstract description 2
- 101000833492 Homo sapiens Jouberin Proteins 0.000 abstract 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 abstract 1
- 102100024407 Jouberin Human genes 0.000 abstract 1
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 abstract 1
- 101710130262 Probable Vpr-like protein Proteins 0.000 abstract 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 216
- 238000001514 detection method Methods 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 11
- 101710189078 Helicase Proteins 0.000 description 9
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 9
- 101710172711 Structural protein Proteins 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 8
- 101710113540 ORF2 protein Proteins 0.000 description 8
- 101710090523 Putative movement protein Proteins 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 241000282887 Suidae Species 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241000725585 Chicken anemia virus Species 0.000 description 5
- 241001533399 Circoviridae Species 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229940027941 immunoglobulin g Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102100031725 Cortactin-binding protein 2 Human genes 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 101710197985 Probable protein Rev Proteins 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 101000818108 Acholeplasma phage L2 Uncharacterized 81.3 kDa protein Proteins 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 101000912350 Haemophilus phage HP1 (strain HP1c1) DNA N-6-adenine-methyltransferase Proteins 0.000 description 2
- 101000790844 Klebsiella pneumoniae Uncharacterized 24.8 kDa protein in cps region Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003746 feather Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241001302800 Beak and feather disease virus Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 238000012369 In process control Methods 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000745220 Pigeon circovirus Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010965 in-process control Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000001739 intranuclear inclusion body Anatomy 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10051—Methods of production or purification of viral material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
Abstract
Description
本出願は、その内容が参照により本明細書中に明確に組み込まれている、2005年4月13日に出願した米国仮出願第60/670,892号の優先権を主張するものである。
該文献中又はその手続遂行において引用された全ての文献(「出願引用文献」)、出願引用文献中で引用され又は参照された全ての文献、本明細書において引用され又は参照された全ての文献(「本明細書における引用文献」)、及び本明細書における引用文献中で引用され又は参照された全ての文献は、本明細書において、若しくは本明細書において参照により組み込まれている任意の文献において記載されている任意の製品の、メーカーによる任意の取扱い説明書、説明書、製品規格、及び製品シートと共に、参照により本明細書中に組み込まれており、本発明の実施において使用され得る。
サーコウイルスPCV2のORF、それらと同等の識別子、及び参照により本明細書中にその全体が組み込まれている各々のそれらの出典を、下記の表1に示す。Meehan et al. (1997; 1998)によって説明されているように、ORF1及びORF2は、代わりにそれぞれORF4及び13として示されてきた。
(a)細胞数及び細胞生存率の決定
ヨウ化プロピジウムを、原形質膜の完全性を評価するために使用した。ヨウ化プロピジウムは、核酸を染色する蛍光生体色素である。死細胞は、Galaxy血球計算器を使用したフローサイトメトリーによって赤色の染色として検出されたヨウ化プロピジウムを取り込む(フローサイトメーターの他の同様の機能モデルを使用し得る)。この血球計算器は、無染色の(生存)細胞、又はヨウ化プロピジウムによって染色された(死)細胞を、識別、検出、計数する性能を有する。使用する血球計算器の特定モデルのメーカー取扱い説明書に従って、200μlの体積中の細胞数を決定する。
1回のアッセイに、ネガティブコントロールのために1×106、ORF1検出のために1×106及びORF2検出のために1×106として分取した、約3×106個の細胞を必要とした。細胞の異なる量のために、試薬の量をそれに応じて適応させた。
(i)固定:BD CytofixCytoperm(BD Biosciences社製、参照番号554714)を使用した。固定剤メーカーの推奨に従って、固定を行った。簡単に言えば、3×106個の細胞を、15ml又は50mlの円錐管中において6分間400gで遠心分離機にかけた。上清を廃棄し、細胞をCytofix750μlと共に再懸濁し、20分間氷上でインキュベーションした。細胞を、1%BSAを含有するPBS1mlで2回洗浄し、1mlのPBS/1%BSA中で再懸濁した。染色する前に、試料を15日まで5℃で保管した。
(ii)ORF1及びORF2の染色:固定された細胞を、6分間400gで遠心分離機にかけた。上清を廃棄し、300μlの1×BD Perm Wash溶液を添加した。100μlの固定した細胞を96マイクロウェルプレートの3つのウェルに分注し、6分間400gで遠心分離機にかけた。上清を廃棄し、100μlの1×BD Perm Wash溶液を添加した。5μlの抗体(1mg/ml)を各ウェルに添加した。通常、5μgのモノクローナル抗体−精製Mab抗PCV2(ORF1)No1991D3GA(初濃度=lmg/ml)又は精製Mab抗PCV2(ORF2)No1903A8BC(初濃度=lmg/ml)で、各々の染色に十分であった。精製Mab抗クロストリジウムNo101B9B又は同等物(初濃度=lmg/ml)をネガティブコントロールとして使用した。
(iii)FCMによる検出:Galaxy血球計算器(Partec社製)などの血球計算器のための設定パラメーターは通常、FSCリニアスケールでは閾値で、FL1ログスケールでは検出された細胞の蛍光であった(FITCチャンネルに対応する)。
図3に示されているように、PK−15細胞上で増殖するPCV2ウイルスのバッチ種培養物のインキュベーション期間の5日目に、宿主細胞の50%が上清中に存在し、大部分が死んでいた(73%)。対照的に、宿主細胞の50%は、CYTODEX(商標)(Amersham Biosciences,Inc社製)基質支持体上に存在し、ほぼ全体的に生存している集団であった(96%)。
図6に示されているように、ORF1では、培養物インキュベーション期間の後期の間に細胞膜に検出されたシグナルはなかった。下記の表2は、CYTODEX(商標)(Amersham Biosciences,Inc社製)に接着した細胞上に膜シグナルが検出されなかったことを示す。主要なORF特異的シグナルは、培養上清からの細胞上にあり、2日目から5日目にかけて上昇していた。結果は、4日目に最高値が60%であり、生細胞又は死細胞で同様であった。
本明細書において引用した文献に従って、300リットル発酵槽にPCV2ウイルスと共に5日間予めインキュベーションしたPK−15細胞の培養物を添加した。培養の3日後に、培地はウシ胎仔血清を含まない増殖培地と交換した。上記の実施例に記載されているように、各々の日に採取された試料について、PK−15細胞生存率並びにORF1及びORF2の発現を試験した。
Claims (9)
- 蛍光抗体細胞選別(FACS)に基づく、ウイルス感染宿主細胞の培養によるサーコウイルス抗原の産生を検出する方法であって、
サーコウイルス抗原の産生が、オープンリーディングフレーム1(ORF1)及びオープンリーディングフレーム2(ORF2)陽性細胞の割合と関連しており、
サーコウイルスに感染した宿主細胞培養物からの、非接着宿主細胞集団と、基質に接着している宿主細胞集団とを含む試料から、(i)非接着宿主細胞及び(ii)基質から離間した接着宿主細胞を単離するステップと、
単離した前記非接着宿主細胞及び前記基質から離間した前記接着宿主細胞中に存在する、(i)オープンリーディングフレーム1(ORF1)陽性細胞の割合、及び(ii)オープンリーディングフレーム2(ORF2)陽性細胞の割合を決定するステップと
を含む方法。 - 蛍光抗体細胞選別(FACS)に基づく、培養宿主細胞からのサーコウイルス産生のインプロセスモニタリング方法であって、
細胞生存率、ORF1及びORF2のレベルの変化をグラフ化することによって、宿主細胞培養物中のサーコウイルス産生の時間経過が決定され、
サーコウイルスに感染した宿主細胞培養物からの、非接着宿主細胞集団と、基質に接着している宿主細胞集団とを含む試料から、(i)非接着宿主細胞及び(ii)基質から離間した接着宿主細胞を単離するステップと、
前記非接着宿主細胞及び接着宿主細胞の細胞生存率を決定するステップと、
単離した前記非接着宿主細胞及び前記基質から離間した前記接着宿主細胞中に存在する、(i)オープンリーディングフレーム1(ORF1)陽性細胞の割合、及び(ii)オープンリーディングフレーム2(ORF2)陽性細胞の割合を決定するステップと
を含む方法。 - 細胞生存率を、フローサイトメトリーを使用してヨウ化プロピジウム取込みを測定することによって決定する、請求項2に記載の方法。
- サーコウイルスの産生方法であって、
サーコウイルスの種培養物を宿主細胞培養物に接種するステップと、
ウシ胎仔血清の非存在下で前記宿主細胞培養物をインキュベートするステップと、
(i)宿主細胞生存率、及び(ii)前記宿主細胞によるORF1及びORF2発現をモニタリングするステップと、
前記宿主細胞培養物の非接着細胞及び接着細胞中のORF2発現がほぼ同一である場合に、前記宿主細胞培養物からサーコウイルスを収穫するステップと
を含む方法。 - 蛍光抗体細胞選別(FACS)に基づく方法を使用して、種培養物中のサーコウイルスの収量を、上清の宿主細胞中のサーコウイルスORF1及びORF2抗原の発現をモニタリングすることによって決定し、ORF2が非接着細胞によって発現する場合に前記種培養物を収穫する、請求項4に記載の方法。
- 細胞生存率を、フローサイトメトリーを使用してヨウ化プロピジウム取込みを測定することによって決定する、請求項4に記載の方法。
- 蛍光抗体細胞選別(FACS)に基づく方法を使用して、ウイルス感染宿主細胞培養物中のORF1及びORF2抗原の発現をモニタリングし、サーコウイルス抗原の産生が、オープンリーディングフレーム1(ORF1)及びオープンリーディングフレーム2(ORF2)陽性細胞FACSの割合と関連している、請求項4に記載の方法。
- サーコウイルスがPCV2である、請求項4に記載の方法。
- 宿主細胞がPK−15である、請求項4に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67089205P | 2005-04-13 | 2005-04-13 | |
US60/670,892 | 2005-04-13 | ||
PCT/US2006/014068 WO2006113435A2 (en) | 2005-04-13 | 2006-04-13 | Method for porcine circovirus production and assays for monitoring production |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008536499A true JP2008536499A (ja) | 2008-09-11 |
JP5408998B2 JP5408998B2 (ja) | 2014-02-05 |
Family
ID=37115731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008506739A Active JP5408998B2 (ja) | 2005-04-13 | 2006-04-13 | ブタサーコウイルス産生アッセイ |
Country Status (21)
Country | Link |
---|---|
US (2) | US7358075B2 (ja) |
EP (2) | EP1869471B1 (ja) |
JP (1) | JP5408998B2 (ja) |
KR (1) | KR101369656B1 (ja) |
CN (1) | CN101194165B (ja) |
BR (1) | BRPI0607540B1 (ja) |
CA (1) | CA2604691C (ja) |
CR (1) | CR9511A (ja) |
CY (1) | CY1117850T1 (ja) |
DK (1) | DK1869471T3 (ja) |
ES (1) | ES2589928T3 (ja) |
HK (1) | HK1121232A1 (ja) |
HR (1) | HRP20161132T1 (ja) |
HU (1) | HUE028343T2 (ja) |
ME (1) | ME02683B (ja) |
MX (1) | MX2007012786A (ja) |
PL (1) | PL1869471T3 (ja) |
PT (1) | PT1869471T (ja) |
RS (1) | RS55085B1 (ja) |
SI (1) | SI1869471T1 (ja) |
WO (1) | WO2006113435A2 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2772047B1 (fr) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
US7700285B1 (en) * | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
US7833707B2 (en) * | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
US20080226594A1 (en) * | 2005-02-03 | 2008-09-18 | Hans Nauwynck | Culturing circular ssdna viruses for the production of vaccines |
HUE051025T2 (hu) * | 2005-12-29 | 2021-01-28 | Boehringer Ingelheim Animal Health Usa Inc | Multivalens PCV2 immunogén készítmények és eljárások ilyen készítmények elõállítására |
EP3766518A1 (en) * | 2005-12-29 | 2021-01-20 | Boehringer Ingelheim Animal Health USA Inc. | Pcv2 immunogenic composition for lessening clinical symptoms in pigs |
EP2101815A4 (en) | 2006-12-11 | 2010-10-06 | Boehringer Ingelheim Vetmed | EFFICIENT PROCESS FOR THE TREATMENT OF PORCINE CIRCOVIRUS AND LAWSONIA INTRACELLULARIS INFECTIONS |
CL2007003648A1 (es) * | 2006-12-15 | 2008-04-11 | Boehringer Ingelheim Vetmed | Metodo para el tratamiento o profilaxis de infeccion por circovirus 2 porcino (pcv2) o para la reduccion de los sintomas clinicos asociados a pcv2 en animales que tienen anticuerpos anti-pcv2 y/o que tienen 1 a 22 dias de edad que comprende administr |
EP1941903A1 (en) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
EP1958644A1 (en) * | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
US8330873B2 (en) * | 2007-03-14 | 2012-12-11 | Larry Silver | Signal demodulator with overmodulation protection |
US8518696B2 (en) | 2007-05-11 | 2013-08-27 | Temasek Life Sciences Laboratory Limited | Production of homogeneous cell line highly permissive to porcine circovirus type 2 (PCV2) infection |
US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
US20110020394A1 (en) * | 2007-12-31 | 2011-01-27 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 orf2 virus like particle with foreign amino acid insertion |
BRPI0907438A2 (pt) * | 2008-01-23 | 2015-08-04 | Boehringer Ingelheim Vetmed | Composições imunogênicas para mycoplasma hyopneumoniae e pcv2 e métodos para produzir tais composições |
TWI627281B (zh) | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物 |
CN101773667A (zh) * | 2010-01-28 | 2010-07-14 | 洛阳普莱柯生物工程有限公司 | 一种猪圆环病毒ii型疫苗制备 |
CN102690790B (zh) * | 2012-04-27 | 2013-09-25 | 成都天邦生物制品有限公司 | 猪圆环病毒2型细胞悬浮培养生产方法 |
WO2014182872A1 (en) | 2013-05-08 | 2014-11-13 | Protatek International, Inc. | Vaccine for pcv2 and mycoplasma |
KR102319843B1 (ko) | 2013-09-25 | 2021-10-29 | 조에티스 서비시즈 엘엘씨 | Pcv2b 분지형 백신 조성물 및 사용 방법 |
EP3052516B1 (en) | 2013-10-02 | 2020-01-01 | Boehringer Ingelheim Animal Health USA Inc. | Pcv2 orf2 protein variant and virus like particles composed thereof |
WO2017019404A1 (en) | 2015-07-24 | 2017-02-02 | Merial, Inc. | High throughput methods for virus quantification |
DE102018010282A1 (de) | 2018-01-17 | 2019-07-18 | Immatics US, Inc. | Verfahren zur Feststellung der Wirksamkeit von viralen Vektoren |
DE102018100967B4 (de) | 2018-01-17 | 2019-08-14 | Immatics US, Inc. | Verfahren zur feststellung der wirksamkeit von viralen vektoren |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001519159A (ja) * | 1997-10-03 | 2001-10-23 | メリアル | ブタサーコウイルス、ワクチンおよび診断試薬 |
JP2003024057A (ja) * | 2000-09-08 | 2003-01-28 | Aventis Behring Gmbh | 生物物質からシルコウイルスを増幅する方法または除去する方法 |
JP2003516142A (ja) * | 1999-12-10 | 2003-05-13 | ファーブル,ダニエル | ウイルスによる真核細胞のinvitro感染 |
WO2004005493A1 (en) * | 2002-07-09 | 2004-01-15 | Baxter International, Inc. | Animal protein free media for cultivation of cells |
JP2004503234A (ja) * | 2000-06-15 | 2004-02-05 | パーデュー・リサーチ・ファウンデーション | ブタの先天性振せん用ワクチン |
WO2005014862A1 (en) * | 2003-02-25 | 2005-02-17 | Medimmune Vaccines, Inc. | Methods of producing inflenza vaccine compositions |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391314B1 (en) * | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
-
2006
- 2006-04-13 HU HUE06750177A patent/HUE028343T2/en unknown
- 2006-04-13 EP EP06750177.5A patent/EP1869471B1/en active Active
- 2006-04-13 US US11/403,497 patent/US7358075B2/en active Active
- 2006-04-13 PT PT67501775T patent/PT1869471T/pt unknown
- 2006-04-13 DK DK06750177.5T patent/DK1869471T3/en active
- 2006-04-13 ME MEP-2016-174A patent/ME02683B/me unknown
- 2006-04-13 RS RS20160699A patent/RS55085B1/sr unknown
- 2006-04-13 SI SI200632090A patent/SI1869471T1/sl unknown
- 2006-04-13 JP JP2008506739A patent/JP5408998B2/ja active Active
- 2006-04-13 WO PCT/US2006/014068 patent/WO2006113435A2/en active Application Filing
- 2006-04-13 CA CA2604691A patent/CA2604691C/en active Active
- 2006-04-13 ES ES06750177.5T patent/ES2589928T3/es active Active
- 2006-04-13 KR KR1020077026312A patent/KR101369656B1/ko active IP Right Grant
- 2006-04-13 PL PL06750177T patent/PL1869471T3/pl unknown
- 2006-04-13 BR BRPI0607540A patent/BRPI0607540B1/pt active IP Right Grant
- 2006-04-13 CN CN2006800205132A patent/CN101194165B/zh active Active
- 2006-04-13 MX MX2007012786A patent/MX2007012786A/es active IP Right Grant
- 2006-04-13 EP EP16164122.0A patent/EP3088893B1/en active Active
-
2007
- 2007-11-12 CR CR9511A patent/CR9511A/es unknown
-
2008
- 2008-04-11 US US12/101,512 patent/US7476507B2/en active Active
- 2008-11-21 HK HK08112728.6A patent/HK1121232A1/xx unknown
-
2016
- 2016-07-27 CY CY20161100740T patent/CY1117850T1/el unknown
- 2016-09-02 HR HRP20161132TT patent/HRP20161132T1/hr unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001519159A (ja) * | 1997-10-03 | 2001-10-23 | メリアル | ブタサーコウイルス、ワクチンおよび診断試薬 |
JP2003516142A (ja) * | 1999-12-10 | 2003-05-13 | ファーブル,ダニエル | ウイルスによる真核細胞のinvitro感染 |
JP2004503234A (ja) * | 2000-06-15 | 2004-02-05 | パーデュー・リサーチ・ファウンデーション | ブタの先天性振せん用ワクチン |
JP2003024057A (ja) * | 2000-09-08 | 2003-01-28 | Aventis Behring Gmbh | 生物物質からシルコウイルスを増幅する方法または除去する方法 |
WO2004005493A1 (en) * | 2002-07-09 | 2004-01-15 | Baxter International, Inc. | Animal protein free media for cultivation of cells |
WO2005014862A1 (en) * | 2003-02-25 | 2005-02-17 | Medimmune Vaccines, Inc. | Methods of producing inflenza vaccine compositions |
Non-Patent Citations (5)
Title |
---|
JPN6011048834; Vet. Immunol. Immunopathol. (2003) vol.94, no.3-4, p.149-161 * |
JPN6011048835; J. Virol. Methods (1998) vol.71, no.2, p.177-186 * |
JPN6011048837; J. Gen. Virol. (2000) vol.81, no.9, p.2281-2287 * |
JPN6011048839; Virology (2001) vol.285, no.1, p.91-99 * |
JPN6012041241; Arch. Virol. (Mar-2005) vol.150, no.3, p.427-441 * |
Also Published As
Publication number | Publication date |
---|---|
US20060246425A1 (en) | 2006-11-02 |
CR9511A (es) | 2008-01-29 |
WO2006113435A3 (en) | 2007-06-21 |
CN101194165B (zh) | 2013-01-09 |
PL1869471T3 (pl) | 2017-02-28 |
PT1869471T (pt) | 2016-08-16 |
ES2589928T3 (es) | 2016-11-17 |
BRPI0607540B1 (pt) | 2017-05-09 |
US7476507B2 (en) | 2009-01-13 |
RS55085B1 (sr) | 2016-12-30 |
MX2007012786A (es) | 2008-01-11 |
CN101194165A (zh) | 2008-06-04 |
BRPI0607540A2 (pt) | 2009-09-15 |
EP1869471A2 (en) | 2007-12-26 |
CA2604691A1 (en) | 2006-10-26 |
KR101369656B1 (ko) | 2014-03-04 |
JP5408998B2 (ja) | 2014-02-05 |
HRP20161132T1 (hr) | 2016-12-02 |
KR20070120603A (ko) | 2007-12-24 |
US20080241821A1 (en) | 2008-10-02 |
EP3088893A1 (en) | 2016-11-02 |
CY1117850T1 (el) | 2017-05-17 |
EP3088893B1 (en) | 2018-02-14 |
SI1869471T1 (sl) | 2016-09-30 |
CA2604691C (en) | 2013-12-31 |
EP1869471B1 (en) | 2016-06-08 |
HK1121232A1 (en) | 2009-04-17 |
DK1869471T3 (en) | 2016-08-01 |
HUE028343T2 (en) | 2016-12-28 |
ME02683B (me) | 2017-06-20 |
US7358075B2 (en) | 2008-04-15 |
WO2006113435A2 (en) | 2006-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5408998B2 (ja) | ブタサーコウイルス産生アッセイ | |
Nawagitgul et al. | Modified indirect porcine circovirus (PCV) type 2-based and recombinant capsid protein (ORF2)-based enzyme-linked immunosorbent assays for detection of antibodies to PCV | |
Trible et al. | Antibody recognition of porcine circovirus type 2 capsid protein epitopes after vaccination, infection, and disease | |
Trible et al. | Genetic variation of porcine circovirus type 2 (PCV2) and its relevance to vaccination, pathogenesis and diagnosis | |
US9770501B2 (en) | Porcine circovirus type 2 (PCV2), immunogenic composition containing the same, test kit, and application thereof | |
Ellis et al. | Isolation of circovirus from lesions of pigs with postweaning multisystemic wasting syndrome. | |
US20100184016A1 (en) | Methods and compositions in the treatment of porcine circoviral infection | |
Li et al. | Characterization of self-assembled virus-like particles of human polyomavirus BK generated by recombinant baculoviruses | |
Trible et al. | Antibody responses following vaccination versus infection in a porcine circovirus-type 2 (PCV2) disease model show distinct differences in virus neutralization and epitope recognition | |
McNeilly et al. | Evaluation of a porcine circovirus type 2–specific antigen-capture enzyme-linked immunosorbent assay for the diagnosis of postweaning multisystemic wasting syndrome in pigs: comparison with virus isolation, immunohistochemistry, and the polymerase chain reaction | |
US20170088821A1 (en) | Methods and compositions for caliciviridae | |
Kiupel | Postweaning Multisystemic Wasting Syndrome (PMWS) in pigs | |
Zielonka et al. | Detection of chimpanzee polyomavirus-specific antibodies in captive and wild-caught chimpanzees using yeast-expressed virus-like particles | |
Knowles | Propagation and assay of BK virus | |
CN114874295B (zh) | 用于检测猪圆环病毒2型特异性记忆B细胞的ELISpot试剂盒及其应用 | |
Ha et al. | Synthetic peptide-derived antibody-based immunohistochemistry for the detection of porcine circovirus 2 in pigs with postweaning multisystemic wasting syndrome | |
Trible | Characterization of the antibody response to vaccination and or infection with porcine circovirus type 2 and identification and characterization of a decoy epitope in the capsid protein | |
Yan | Prevalence of porcine circovirus type 2 (PCV2) in the US national swine herd | |
Trinh | Virologic, antigenic and genetic characterization of chicken anemia virus (CAV) and development of a new serologic diagnostic method | |
Dai | Virologic, antigenic and genetic characterization of | |
Kummrow | Seroprevalence and association with Disease of Feline Coronaviruses (FCoV) serotype 1 and 2 in Switzerland | |
Sanchez et al. | Pathogenesis of porcine circovirus 2 infections in pigs from foetal to early postnatal life | |
Oka et al. | Sapovirus re-infection gastroenteritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090403 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110913 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120807 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121024 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121031 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121130 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121207 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121220 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130205 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131031 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131105 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5408998 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |